Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by DJDawg on Feb 11, 2024 8:54am

GBM

One huge challenge with recruiting patients for NMIBC is that you are competing for patients with other studies. If you look at the number of patients treated by IBRX and CGON in relation to the number of recruitment sites it is quite the ratio. They too have a huge number of sites but the number of total patients they get is not that impressive.

When TLT gets going on GBM they won't have quite the same challenge. There is so little out there to offer GBM patients sadly. Since they are based in TO they would almost certainly do the phase 1a/b out of that city. If you look at clinicaltrials.gov the number of GBM studies being run out of Toronto are very few and most don't apply unless you have some highly specific criteria. That is why GBM patients have such a hard time, there is so little out there.

So, for future reference, when they go to GBM they may have a faster go at getting patients and results compared to NMIBC.
Comment by Alamir1111 on Feb 11, 2024 12:56pm
Sounds good .Why don't they raise  a separate funding for gbm and get it going ?  ?
Comment by Alamir1111 on Feb 11, 2024 2:04pm
8 years ago https://stockhouse.com/news/press-releases/2016/10/28/theralase-increases-gbm-brain-cancer-survival-by-925
Comment by Alamir1111 on Feb 11, 2024 3:40pm
DR Lothar lilge .Dont know the time when article was published?https://vitusprivatklinik.com/en/blog-and-news-en/vitus-private-clinic-establishes-cooperation-with-prof-lothar-lilge/
Comment by Alamir1111 on Feb 11, 2024 3:59pm
https://vitusprivatklinik.com/en/blog-and-news-en/photodynamic-therapy-with-chlorin-e6/
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250